<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="acn370036" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id><journal-id journal-id-type="publisher-id">ACN3</journal-id><journal-title-group><journal-title>Annals of Clinical and Translational Neurology</journal-title></journal-title-group><issn pub-type="epub">2328-9503</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40129269</article-id><article-id pub-id-type="pmc">PMC12093329</article-id>
<article-id pub-id-type="doi">10.1002/acn3.70036</article-id><article-id pub-id-type="publisher-id">ACN370036</article-id><article-id pub-id-type="other">ACN3-2024-11-1287.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Epitope Mapping of Anti&#x02010;Neurofascin 155 Antibody in a Large Cohort of Autoimmune Nodopathy Patients</article-title></title-group><contrib-group><contrib id="acn370036-cr-0001" contrib-type="author"><name><surname>Abdelhadi</surname><given-names>Amina A.</given-names></name><xref rid="acn370036-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acn370036-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acn370036-cr-0002" contrib-type="author"><name><surname>Ogata</surname><given-names>Hidenori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8932-9731</contrib-id><xref rid="acn370036-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acn370036-cr-0003" contrib-type="author"><name><surname>Zhang</surname><given-names>Xu</given-names></name><xref rid="acn370036-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acn370036-cr-0004" contrib-type="author"><name><surname>Tashiro</surname><given-names>Takumi</given-names></name><xref rid="acn370036-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acn370036-cr-0005" contrib-type="author"><name><surname>Yamasaki</surname><given-names>Ryo</given-names></name><xref rid="acn370036-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acn370036-cr-0006" contrib-type="author"><name><surname>Kira</surname><given-names>Jun&#x02010;ichi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5307-2671</contrib-id><xref rid="acn370036-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="acn370036-cr-0007" contrib-type="author" corresp="yes"><name><surname>Isobe</surname><given-names>Noriko</given-names></name><xref rid="acn370036-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>isobe.noriko.342@m.kyushu-u.ac.jp</email></address></contrib></contrib-group><aff id="acn370036-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Neurological Institute, Graduate School of Medical Sciences, Kyushu University</institution>
<city>Fukuoka</city>
<country country="JP">Japan</country>
</aff><aff id="acn370036-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Microbiology and Immunology, Faculty of Medicine</named-content>
<institution>Zagazig University</institution>
<city>Zagazig</city>
<country country="EG">Egypt</country>
</aff><aff id="acn370036-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Translational Neuroscience Research Center, Graduate School of Medicine</named-content>
<institution>International University of Health and Welfare</institution>
<city>Okawa</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Noriko Isobe (<email>isobe.noriko.342@m.kyushu-u.ac.jp</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>12</volume><issue seq="160">5</issue><issue-id pub-id-type="doi">10.1002/acn3.v12.5</issue-id><fpage>1034</fpage><lpage>1042</lpage><history>
<date date-type="rev-recd"><day>17</day><month>2</month><year>2025</year></date>
<date date-type="received"><day>27</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>06</day><month>3</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 American Neurological Association--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals LLC on behalf of American Neurological Association.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ACN3-12-1034.pdf"/><abstract><title>ABSTRACT</title><sec id="acn370036-sec-0001"><title>Objective</title><p>Autoimmune nodopathy (AN), a newly recognized disease entity, is an immune&#x02010;mediated polyneuropathy involving autoantibodies against cell adhesion molecules located in nodes of Ranvier and paranodal regions, such as neurofascin 186 (NF186) and neurofascin 155 (NF155). The present study aimed to identify the epitopes for autoantibodies against NF155 in a large cohort of Japanese patients with anti&#x02010;NF155 antibody&#x02010;positive (anti&#x02010;NF155+) AN.</p></sec><sec id="acn370036-sec-0002"><title>Methods</title><p>Human embryonic kidney 293 cells stably expressing NF155, NF186, or the third to fourth fibronectin type III domain region (Fn3&#x02010;Fn4) of NF155, as well as cells transiently expressing Fn3, Fn4, or the shorter Fn3&#x02010;Fn4 region of NF155, were developed. Western blotting and flow cytometric cell&#x02010;based assay (CBA) analyses were performed to determine the expression levels of the proteins and identify their target epitopes in serum samples from 100 IgG4 anti&#x02010;NF155+ patients, four non&#x02010;IgG4 anti&#x02010;NF155+ patients, and eight healthy controls.</p></sec><sec id="acn370036-sec-0003"><title>Results</title><p>The expression levels of NF186, NF155, Fn3&#x02010;Fn4 of NF155, and the other truncation variants of NF155 were confirmed by western blotting and flow cytometric CBA. Flow cytometric CBA analysis showed that the autoantibodies in all 104 anti&#x02010;NF155+ patients bound to Fn3&#x02010;Fn4. No autoantibodies reacted with NF186, Fn4, or shorter Fn3&#x02010;Fn4, although the autoantibodies in one IgG4 anti&#x02010;NF155+ patient (1.0%) recognized Fn3 in addition to Fn3&#x02010;Fn4. Western blotting analysis of representative samples generally reproduced the CBA results.</p></sec><sec id="acn370036-sec-0004"><title>Interpretation</title><p>The present study involving a large cohort of patients clarified that the primary epitope for anti&#x02010;NF155 antibodies is located in the Fn3&#x02010;Fn4 region, but not in the Fn3 or Fn4 domains alone.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="acn370036-kwd-0001">autoantibody</kwd><kwd id="acn370036-kwd-0002">autoimmune nodopathy</kwd><kwd id="acn370036-kwd-0003">epitope</kwd><kwd id="acn370036-kwd-0004">IgG4</kwd><kwd id="acn370036-kwd-0005">neurofascin 155</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>The Japan Society for the Promotion of Science (JSPS) KAKENHI
</institution><institution-id institution-id-type="doi">10.13039/501100001691</institution-id></institution-wrap></funding-source><award-id>JP18K15454</award-id><award-id>JP19K17036</award-id><award-id>JP20K16602</award-id><award-id>JP21K07464</award-id><award-id>JP24K10644</award-id><award-id>10.13039/501100001691</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Egyptian Ministry of Higher Education
</institution><institution-id institution-id-type="doi">10.13039/501100002385</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>The Japan Agency for Medical Research and Development (AMED)
</institution><institution-id institution-id-type="doi">10.13039/100009619</institution-id></institution-wrap></funding-source><award-id>JP20ek0109376</award-id><award-id>JP21zf0127004</award-id><award-id>JP23ek0109547</award-id></award-group><funding-statement>This work was funded by <funding-source><institution-wrap><institution>The Japan Society for the Promotion of Science (JSPS) KAKENHI
</institution><institution-id institution-id-type="doi">10.13039/501100001691</institution-id></institution-wrap></funding-source> grants <award-id>JP18K15454</award-id>, <award-id>JP19K17036</award-id>, <award-id>JP20K16602</award-id>, <award-id>JP21K07464</award-id>, <award-id>JP24K10644</award-id>, and <award-id>10.13039/501100001691</award-id>; <funding-source><institution-wrap><institution>Egyptian Ministry of Higher Education
</institution><institution-id institution-id-type="doi">10.13039/501100002385</institution-id></institution-wrap></funding-source>; <funding-source><institution-wrap><institution>The Japan Agency for Medical Research and Development (AMED)
</institution><institution-id institution-id-type="doi">10.13039/100009619</institution-id></institution-wrap></funding-source> grants <award-id>JP20ek0109376</award-id>, <award-id>JP21zf0127004</award-id>, and <award-id>JP23ek0109547</award-id>.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="9"/><word-count count="6000"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="acn370036-ntgp-0001"><fn fn-type="funding" id="acn370036-note-0001"><p>
<bold>Funding:</bold> This study was supported by The Japan Agency for Medical Research and Development (AMED), Grant Number JP20ek0109376, JP21zf0127004, JP23ek0109547 and 10.13039/501100001691, and by The Japan Society for the Promotion of Science (JSPS) KAKENHI, Grant Numbers JP18K15454, JP19K17036, JP20K16602, JP21K07464, and JP24K10644.</p></fn></fn-group></notes></front><body id="acn370036-body-0001"><sec id="acn370036-sec-0005"><label>1</label><title>Introduction</title><p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous acquired immune&#x02010;mediated neurological disorder that affects the peripheral nerves and nerve roots [<xref rid="acn370036-bib-0001" ref-type="bibr">1</xref>, <xref rid="acn370036-bib-0002" ref-type="bibr">2</xref>]. On the basis of the clinical heterogeneity, distinct immunopathological mechanisms may underlie the various subtypes of CIDP, such as differences in immune responses or antigen specificities [<xref rid="acn370036-bib-0003" ref-type="bibr">3</xref>]. The pathogenesis of CIDP is primarily considered to involve T cells and macrophage&#x02010;mediated demyelination, although circulating humoral factors, such as autoantibodies, and activated plasma cells may also play roles [<xref rid="acn370036-bib-0004" ref-type="bibr">4</xref>, <xref rid="acn370036-bib-0005" ref-type="bibr">5</xref>]. A recent study found that approximately 10% of CIDP patients possess autoantibodies against cell adhesion molecules located in nodes of Ranvier and paranodal regions, such as contactin&#x02010;1 (CNTN1), contactin&#x02010;associated protein&#x02010;1 (Caspr1), neurofascin 155 (NF155), and neurofascin 140/186 (NF140/186) [<xref rid="acn370036-bib-0006" ref-type="bibr">6</xref>]. In the latest update of the European Academy of Neurology/Peripheral Nerve Society CIDP diagnostic criteria, the distinctive characteristics of patients with these nodal/paranodal antibodies led to the establishment of a novel diagnostic category, termed autoimmune nodopathy (AN) [<xref rid="acn370036-bib-0007" ref-type="bibr">7</xref>]. Subclass analyses of the paranodal autoantibodies revealed a predominance of IgG4. However, IgG3 and IgG2 autoantibodies have also been detected, and these may be linked to rapid disease progression or a monophasic course [<xref rid="acn370036-bib-0008" ref-type="bibr">8</xref>].</p><p>Neurofascins (NFs) belong to the immunoglobulin superfamily, a large group of cell surface proteins with one or more extracellular immunoglobulin&#x02010;like (Ig) domains [<xref rid="acn370036-bib-0009" ref-type="bibr">9</xref>]. The major NF isoforms, NF186, NF155, and NF140, are generated and expressed in neural tissues by alternative splicing. Myelin terminal loops express NF155 in paranodes, where it interacts with axonal CNTN1 and Caspr1 to form a septal barrier that prevents the nodal complex from entering internodes [<xref rid="acn370036-bib-0010" ref-type="bibr">10</xref>]. NF186, a nodal NF isoform, has been implicated in dynamic synaptic stability, neuronal outgrowth, and sodium channel clustering [<xref rid="acn370036-bib-0009" ref-type="bibr">9</xref>]. NFs consist of six Ig domains, up to five fibronectin type III (Fn) domains, a transmembrane domain, and a short cytoplasmic domain [<xref rid="acn370036-bib-0009" ref-type="bibr">9</xref>]. The extracellular domains of NF155 and NF186 have the following differences: NF155 contains the first four Fn domains (Fn1&#x02010;Fn4), while NF186 lacks Fn3 and has a mucin domain between Fn4 and Fn5 (Figure&#x000a0;<xref rid="acn370036-fig-0001" ref-type="fig">1A</xref>) [<xref rid="acn370036-bib-0011" ref-type="bibr">11</xref>]. Although the precise functions of the Fn domains in NF155 remain to be elucidated, Fn3 of NF155 was reported to promote neural cell adhesion and neurite outgrowth [<xref rid="acn370036-bib-0012" ref-type="bibr">12</xref>]. Therefore, this domain has the potential to bind to glial/axonal partners and play a role in paranode formation or stabilization [<xref rid="acn370036-bib-0013" ref-type="bibr">13</xref>].</p><fig position="float" fig-type="FIGURE" id="acn370036-fig-0001"><label>FIGURE 1</label><caption><p>Domain structures and expression analysis of the NF isoforms and NF155 truncation variants used for epitope mapping. (A) The domain organizations of the NF isoforms (NF155 and NF186) and the truncated variants of NF155 (Fn3&#x02010;Fn4, Fn3, Fn4, and shorter Fn3&#x02010;Fn4) are shown. (B) In western blotting analyses, specific bands of NF155 and NF186, conjugated with tGFP, were obtained with an anti&#x02010;tGFP antibody. (C) The expression of each truncated variant conjugated with a FLAG tag and a GPI anchor was confirmed with an anti&#x02010;FLAG antibody. Two bands were observed for Fn4, the larger of which appeared to be a dimer. Fn3, third fibronectin type III domain; Fn4, fourth fibronectin type III domain; GPI, glycosylphosphatidylinositol; HEK293, human embryonic kidney 293 cells; M, molecular weight markers; m, mucin domain; NF, neurofascin; NF155, neurofascin 155; NF186, neurofascin 186; tGFP, turbo GFP.</p></caption><graphic xlink:href="ACN3-12-1034-g002" position="anchor" id="jats-graphic-1"/></fig><p>AN patients with IgG4 anti&#x02010;NF155 antibodies exhibit unique features compared with autoantibody&#x02010;negative CIDP patients, including higher frequencies of human leukocyte antigen (HLA)&#x02010;<italic toggle="yes">DRB1*15</italic> alleles, primary distal motor involvement, ataxia and low&#x02010;frequency tremor, and slower conduction delay on nerve conduction studies [<xref rid="acn370036-bib-0014" ref-type="bibr">14</xref>, <xref rid="acn370036-bib-0015" ref-type="bibr">15</xref>]. Meanwhile, the IgG4 autoantibodies in these patients do not activate the complement pathway, mediate demyelination by stimulated macrophages, or induce inflammation; instead, they block functional protein&#x02013;protein interactions at the paranodal axoglial junction, resulting in conduction breakdown [<xref rid="acn370036-bib-0016" ref-type="bibr">16</xref>, <xref rid="acn370036-bib-0017" ref-type="bibr">17</xref>, <xref rid="acn370036-bib-0018" ref-type="bibr">18</xref>, <xref rid="acn370036-bib-0019" ref-type="bibr">19</xref>]. These observations are consistent with the electron microscopy findings for the sural nerves in patients with anti&#x02010;NF155 antibodies, which revealed detachment of the paranodal myelin terminal loops from the axolemma without inflammatory cell infiltration [<xref rid="acn370036-bib-0020" ref-type="bibr">20</xref>]. Furthermore, the IgG4 autoantibodies exhibited a pathogenic role in rodents, as their passive transfer reduced NF155 expression and prevented the formation of the NF155/Caspr1/CNTN1 complex [<xref rid="acn370036-bib-0018" ref-type="bibr">18</xref>]. In a recent multicenter international study, rituximab was effective in &#x0003e;&#x02009;80% of anti&#x02010;NF155 antibody&#x02010;positive (anti&#x02010;NF155+) AN patients who showed a poor response to intravenous immunoglobulins [<xref rid="acn370036-bib-0019" ref-type="bibr">19</xref>]. Furthermore, rituximab was efficiently directed against CD20&#x02010;positive short&#x02010;lived plasma cells producing IgG4 and their CD20&#x02010;positive precursors [<xref rid="acn370036-bib-0021" ref-type="bibr">21</xref>], resulting in decreased B lymphocyte counts and serum IgG4 levels [<xref rid="acn370036-bib-0021" ref-type="bibr">21</xref>, <xref rid="acn370036-bib-0022" ref-type="bibr">22</xref>, <xref rid="acn370036-bib-0023" ref-type="bibr">23</xref>, <xref rid="acn370036-bib-0024" ref-type="bibr">24</xref>].</p><p>Identifying epitopes recognized by autoantibodies can lead to a better understanding of disease mechanisms, more precise diagnosis, and the development of epitope&#x02010;specific therapeutic agents [<xref rid="acn370036-bib-0025" ref-type="bibr">25</xref>]. An epitope mapping study that evaluated 38 IgG4 anti&#x02010;NF155+ patients speculated that the Fn1&#x02010;Fn4 region contains the primary target epitope for the anti&#x02010;IgG4 NF155 antibodies [<xref rid="acn370036-bib-0013" ref-type="bibr">13</xref>], but it included some inconsistencies. Two other studies that investigated only four IgG4 anti&#x02010;NF155+ patients in total demonstrated that their sera reacted with the Fn3&#x02010;Fn4 region of NF155, but not with the Fn3 or Fn4 domains alone [<xref rid="acn370036-bib-0008" ref-type="bibr">8</xref>, <xref rid="acn370036-bib-0026" ref-type="bibr">26</xref>]. Therefore, detailed epitope mapping of anti&#x02010;NF155 antibodies remains elusive.</p><p>In the present study, we aimed to identify the epitopes for anti&#x02010;NF155 antibodies in a large cohort of Japanese patients with anti&#x02010;NF155+ AN.</p></sec><sec sec-type="methods" id="acn370036-sec-0006"><label>2</label><title>Methods</title><sec id="acn370036-sec-0007"><label>2.1</label><title>Subjects</title><p>The study enrolled 104 consecutive patients whose serum samples were found to be positive for total IgG anti&#x02010;NF155 antibodies by flow cytometric cell&#x02010;based assay (CBA) performed at Kyushu University. The samples were collected from the patients between 2008 and 2022. The 104 patients were subdivided into two groups based on their antibody subclass findings as follows: a group of 100 patients who were positive for IgG4 anti&#x02010;NF155 antibodies (IgG4 anti&#x02010;NF155+ patients) and a group of four patients who were positive for total IgG anti&#x02010;NF155 antibodies but negative for IgG4 anti&#x02010;NF155 antibodies (non&#x02010;IgG4 anti&#x02010;NF155+ patients). Sera from eight healthy subjects were also included as negative controls. The research protocols for the study were approved by the Kyushu University Ethics Committee. An opt&#x02010;out recruitment method was adopted for the study.</p></sec><sec id="acn370036-sec-0008"><label>2.2</label><title>Development of Plasmid Vectors Encoding <styled-content style="fixed-case" toggle="no">NF155</styled-content> Truncation Variants</title><p>The NF155 fragments examined in the study were Fn3&#x02010;Fn4 (amino acid residues 836&#x02013;1046), Fn3 (amino acid residues 836&#x02013;942), Fn4 (amino acid residues 943&#x02013;1046), and shorter Fn3&#x02010;Fn4 (amino acid residues 893&#x02013;986) (Table&#x000a0;<xref rid="acn370036-tbl-0001" ref-type="table">1</xref> and Figure&#x000a0;<xref rid="acn370036-fig-0001" ref-type="fig">1A</xref>). DNA fragments encoding these NF155 fragments were constructed by artificial DNA synthesis (FASMAC, Kanagawa, Japan) with a FLAG tag and glycosylphosphatidylinositol (GPI) anchor conjugation, and then cloned into pcDNA3.1/Zeo<sup>(+)</sup> (Thermo Fisher Scientific, Waltham, MA).</p><table-wrap position="float" id="acn370036-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Summary of the domains cloned for expression in HEK293 cells.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Region in NF155</th><th align="center" valign="bottom" rowspan="1" colspan="1">Protein fragment amino acid sequences defined by the NCBI</th><th align="center" valign="bottom" rowspan="1" colspan="1">Protein fragment amino acid sequences in the present study</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Fn3&#x02010;Fn4</td><td align="center" valign="top" rowspan="1" colspan="1">Ala839&#x02010;Ser1034</td><td align="center" valign="top" rowspan="1" colspan="1">Pro836&#x02010;Ala1046</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fn3</td><td align="center" valign="top" rowspan="1" colspan="1">Ala839&#x02010;Thr938</td><td align="center" valign="top" rowspan="1" colspan="1">Pro836&#x02010;Val942</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fn4</td><td align="center" valign="top" rowspan="1" colspan="1">Pro943&#x02010;Ser1034</td><td align="center" valign="top" rowspan="1" colspan="1">Pro943&#x02010;Ala1046</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shorter Fn3&#x02010;Fn4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Gln893&#x02010;Ile986</td></tr></tbody></table><table-wrap-foot id="acn370036-ntgp-0002"><fn id="acn370036-note-0002"><p>Abbreviations: Fn3, third fibronectin type III domain; Fn4, fourth fibronectin type III domain; HEK293, human embryonic kidney 293 cells; NCBI, National Center for Biotechnology Information; NF155, neurofascin 155.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acn370036-sec-0009"><label>2.3</label><title>Development of Stable Cell Lines Expressing <styled-content style="fixed-case" toggle="no">NF186</styled-content>, <styled-content style="fixed-case" toggle="no">NF155</styled-content>, and Fn3&#x02010;Fn4 of <styled-content style="fixed-case" toggle="no">NF155</styled-content>
</title><p>In addition to human embryonic kidney 293 (HEK293) cell lines stably expressing NF155 or NF186 with turbo GFP (tGFP) established in a previous study [<xref rid="acn370036-bib-0027" ref-type="bibr">27</xref>], HEK293 cells stably expressing Fn3&#x02010;Fn4&#x02010;FLAG&#x02010;GPI anchor were newly developed for the present study. Briefly, the vector was transfected into naive HEK293 cells using FuGENE 6 Transfection Reagent (Promega Corporation, Madison, WI) in accordance with the manufacturer's instructions. The transfected cells were cultured in selection medium containing G418 (Thermo Fisher Scientific). When single colonies of adequate size for clonal expansion had formed, individual colonies were picked up using a sterile cloning cylinder and scaled up to larger volumes.</p></sec><sec id="acn370036-sec-0010"><label>2.4</label><title>Transient Expression of Various <styled-content style="fixed-case" toggle="no">NF155</styled-content> Truncation Variants in <styled-content style="fixed-case" toggle="no">HEK293</styled-content> Cells</title><p>The epitope mapping vectors encoding Fn3, Fn4, or shorter Fn3&#x02010;Fn4 conjugated with a FLAG tag and a GPI anchor were separately transfected into HEK293 cells using FuGENE 6 Transfection Reagent (Promega Corporation) in accordance with the manufacturer's instructions. After incubation at 37&#x000b0;C for 24&#x02013;48&#x02009;h, the cells were processed for experiments.</p></sec><sec id="acn370036-sec-0011"><label>2.5</label><title>Western Blot Analysis</title><p>Cells stably expressing NF155, NF186, or Fn3&#x02010;Fn4 and cells transiently expressing Fn3, Fn4, or shorter Fn3&#x02010;Fn4 were lysed with radioimmunoprecipitation buffer containing a protease inhibitor cocktail and 0.5% sodium dodecyl sulfate (SDS) (Nacalai Tesque, Kyoto, Japan). Cell lysates from naive HEK293 cells were used as a negative control.</p><p>The protein concentrations in the cell lysates were measured using a BCA Protein Assay Kit (Thermo Fisher Scientific). The cell lysates were then mixed with Laemmli buffer and heated at 95&#x000b0;C for 3&#x02009;min. Subsequently, the samples were electrophoresed in 7.5% mini PROTEAN precast gradient gels (Bio&#x02010;Rad, Hercules, CA), transferred onto polyvinylidene fluoride membranes, blocked with 3% skim milk, and incubated with patient sera (1:1000 dilution) or the following primary antibodies: mouse anti&#x02010;FLAG antibody (FUJIFILM Wako Chemicals, Osaka, Japan; 1:2000 dilution); rabbit anti&#x02010;tGFP antibody (Evrogen, Moscow, Russia; 1:5000 dilution). NF155&#x02010;tGFP and NF186&#x02010;tGFP were specifically detected using the anti&#x02010;tGFP antibody, while Fn3, Fn4, Fn3&#x02010;Fn4, and shorter Fn3&#x02010;Fn4&#x02010;FLAG&#x02010;GPI anchor were detected using the anti&#x02010;FLAG antibody. After washing, the membranes were incubated with secondary antibodies (1:20,000 dilution) for 1&#x02009;h at room temperature. The following secondary antibodies were used: horseradish peroxidase (HRP)&#x02010;conjugated goat antihuman IgG Fc antibody (Abcam, Cambridge, UK); HRP&#x02010;conjugated horse anti&#x02010;mouse IgG antibody (Vector Laboratories, Burlingame, CA); HRP&#x02010;conjugated goat anti&#x02010;rabbit IgG antibody (Vector Laboratories). After treatment with ECL Prime Western Blotting Detection Reagent (GE Healthcare, Chicago, IL), the membrane&#x02010;bound antibodies were identified and analyzed using a ChemiDoc XRS System (Bio&#x02010;Rad).</p></sec><sec id="acn370036-sec-0012"><label>2.6</label><title>Cell&#x02010;Based Assay of Transiently Transfected Cells and Stable Cell Lines by Flow Cytometry</title><p>The cell lines stably expressing NF155, NF186, or Fn3&#x02010;Fn4 were separately mixed with naive HEK293 cells and resuspended in Dulbecco's modified Eagle's medium containing 1% fetal bovine serum and 1&#x02009;mmol/L ethylenediaminetetraacetic acid (EDTA) (FCM buffer) at a concentration of 1.0&#x02009;&#x000d7;&#x02009;10 [<xref rid="acn370036-bib-0006" ref-type="bibr">6</xref>] cells/mL. At 24&#x02013;48&#x02009;h after transfection with the vectors encoding Fn3, Fn4, or shorter Fn3&#x02010;Fn4, the cells were resuspended in FCM buffer at a concentration of 1.0&#x02009;&#x000d7;&#x02009;10 [<xref rid="acn370036-bib-0006" ref-type="bibr">6</xref>] cells/mL. Serum samples were mixed with 50&#x02009;&#x003bc;L of cell&#x02010;containing solution at a final dilution of 1:200. After incubation at room temperature for 90&#x02009;min on a shaker, the cells were washed. Bound autoantibodies were detected using an Alexa Fluor 647&#x02010;conjugated antihuman IgG antibody (Thermo Fisher Scientific; 1:500 dilution). After incubation at room temperature for 40&#x02009;min on a shaker, the cells were washed and resuspended in 100&#x02009;&#x003bc;L of phosphate&#x02010;buffered saline containing 5&#x02009;mmol/L EDTA and analyzed using a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany).</p><p>As a positive control, purified IgG from one IgG4 anti&#x02010;NF155+ patient was examined. Expression of NF186 was confirmed using a rabbit anti&#x02010;NF186 antibody (Chemicon International, Temecula, CA; 1:500 dilution) and an Alexa Fluor 647&#x02010;conjugated anti&#x02010;rabbit IgG antibody (Thermo Fisher Scientific; 1:500 dilution). An Alexa Fluor 647&#x02010;conjugated anti&#x02010;FLAG antibody (MBL, Tokyo, Japan; 1:500 dilution) was used to detect Fn3, Fn4, Fn3&#x02010;Fn4, and shorter Fn3&#x02010;Fn4.</p><p>FlowJo software version 10.8.1 (Becton Dickinson, San Jose, CA) was used to analyze the flow cytometry data and prepare the figures. Flow cytometric histograms were created to evaluate the relative fluorescence intensities of Alexa Fluor 647 (Figure&#x000a0;<xref rid="acn370036-fig-0002" ref-type="fig">2</xref>). As positive controls, purified IgG from one IgG4 anti&#x02010;NF155+ patient, rabbit anti&#x02010;NF186 antibody, and anti&#x02010;FLAG antibody were used to detect NF155, NF186, and the truncated variants of NF155, respectively. Serum from a healthy control was adopted as a negative control. Positive flow cytometry results were defined as histograms exhibiting two peaks representing cells with and without the target proteins captured by the autoantibodies. Histograms showing only one peak were defined as negative flow cytometry results.</p><fig position="float" fig-type="FIGURE" id="acn370036-fig-0002"><label>FIGURE 2</label><caption><p>Flow cytometric CBA for the reactivities of anti&#x02010;NF155+ patient sera against specific NF isoforms and truncated variants of NF155. The <italic toggle="yes">X</italic>&#x02010;axis and <italic toggle="yes">Y</italic>&#x02010;axis in each histogram indicate the fluorescence intensity of Alexa Fluor 647 and the cell count, respectively. Rows 1 and 2 show representative histograms of positive and negative controls, respectively. The flow cytometric CBA results for representative serum samples from five IgG4 anti&#x02010;NF155+ patients (Pts. 1, 2, 7, 63, 100; blue) and one non&#x02010;IgG4 anti&#x02010;NF155+ patient (Pt. 104; green) are shown in rows 3&#x02013;8. All serum samples from the six patients were reactive toward NF155 but not NF186. Epitope analysis using the NF155 truncation variants showed that the reactivity against Fn3&#x02010;Fn4 was present in all serum samples positive for full&#x02010;length NF155. None of the patient sera were reactive toward Fn4 and shorter Fn3&#x02010;Fn4. The serum sample from only one IgG4 anti&#x02010;NF155+ patient (Pt. 1) reacted with Fn3. Fn3, third fibronectin type III domain; Fn4, fourth fibronectin type III domain; NF, neurofascin; NF155, neurofascin 155; NF186, neurofascin 186; Pt., Patient; tGFP, turbo GFP.</p></caption><graphic xlink:href="ACN3-12-1034-g003" position="anchor" id="jats-graphic-3"/></fig></sec></sec><sec sec-type="results" id="acn370036-sec-0013"><label>3</label><title>Results</title><sec id="acn370036-sec-0014"><label>3.1</label><title>Demographic Data, Clinical Characteristics, and Laboratory Data for the Anti&#x02010;<styled-content style="fixed-case" toggle="no">NF155</styled-content>+ Patients</title><p>The demographic, clinical, and laboratory characteristics for the 100 IgG4 anti&#x02010;NF155+ patients and four non&#x02010;IgG4 anti&#x02010;NF155+ patients are summarized in Table&#x000a0;<xref rid="acn370036-tbl-0002" ref-type="table">2</xref>. Their mean ages at onset were early to mid&#x02010;30s, relatively younger than those of general CIDP patients. The symptoms and neurological findings were usually symmetrical, and &#x0003e;&#x02009;40% of the patients predominantly exhibited distal manifestations. All patients met definite European Federation of Neurological Societies/Peripheral Nerve Society electrophysiological criteria for CIDP except for one IgG4 anti&#x02010;NF155+ patient, in whom compound muscle action potentials were not evoked in any nerves. The mean CSF protein levels were highly elevated in both groups.</p><table-wrap position="float" id="acn370036-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Demographic and laboratory parameters in the IgG4 anti&#x02010;NF155+ and non&#x02010;IgG4 anti&#x02010;NF155+ AN patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">IgG4 anti&#x02010;NF155+ AN (<italic toggle="yes">N</italic>&#x02009;=&#x02009;100)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#x02010;IgG4 anti&#x02010;NF155+ AN (<italic toggle="yes">N</italic>&#x02009;=&#x02009;4)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="3" valign="top" rowspan="1">Demographic data</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Sex ratio, male:female</td><td align="center" valign="top" rowspan="1" colspan="1">82:18</td><td align="center" valign="top" rowspan="1" colspan="1">2:2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age at onset (years), mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" valign="top" rowspan="1" colspan="1">33.0&#x02009;&#x000b1;&#x02009;17.2</td><td align="center" valign="top" rowspan="1" colspan="1">35.0&#x02009;&#x000b1;&#x02009;16.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Age at sample collection (years), mean&#x02009;&#x000b1;&#x02009;SD<xref rid="acn370036-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">37.8&#x02009;&#x000b1;&#x02009;17.9</td><td align="center" valign="top" rowspan="1" colspan="1">44.3&#x02009;&#x000b1;&#x02009;10.4</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Disease duration (months), median (IQR)<xref rid="acn370036-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">15 (6.5, 64)</td><td align="center" valign="top" rowspan="1" colspan="1">107 (22, 212.25)</td></tr><tr><td align="left" colspan="3" valign="top" rowspan="1">Clinical subtypes<xref rid="acn370036-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Typical, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (53)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (50)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">DADS, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (43)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (50)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MADSAM, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pure sensory, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Definite electrophysiological criteria, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">99 (99)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CSF protein amounts (mg/dL), mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" valign="top" rowspan="1" colspan="1">342&#x02009;&#x000b1;&#x02009;186</td><td align="center" valign="top" rowspan="1" colspan="1">273&#x02009;&#x000b1;&#x02009;128</td></tr></tbody></table><table-wrap-foot id="acn370036-ntgp-0003"><fn id="acn370036-note-0003"><p>Abbreviations: AN, autoimmune nodopathy; CSF, cerebrospinal fluid; DADS, distal acquired demyelinating symmetric neuropathy; IQR, interquartile range; MADSAM, multifocal acquired demyelinating sensory and motor neuropathy; <italic toggle="yes">N</italic>, number of patients collated; <italic toggle="yes">n</italic>, number of positive patients; NF155, neurofascin 155; SD, standard deviation.</p></fn><fn id="acn370036-note-0004"><label>
<sup>a</sup>
</label><p>Data for two patients were missing among the IgG4 anti&#x02010;NF155+ AN patients.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acn370036-sec-0015"><label>3.2</label><title>Confirmation of Expression of <styled-content style="fixed-case" toggle="no">NF155</styled-content>, <styled-content style="fixed-case" toggle="no">NF186</styled-content>, and <styled-content style="fixed-case" toggle="no">NF155</styled-content> Domains in <styled-content style="fixed-case" toggle="no">HEK293</styled-content> Cells</title><p>The expression of the recombinant proteins in the cell lines was confirmed by western blotting (Figure&#x000a0;<xref rid="acn370036-fig-0001" ref-type="fig">1B,C</xref>). Two bands were noted for Fn4, suggesting the presence of a dimer (Figure&#x000a0;<xref rid="acn370036-fig-0001" ref-type="fig">1C</xref>).</p><p>The flow cytometric CBA also confirmed the protein expression. The purified IgG from one IgG4 anti&#x02010;NF155+ patient, anti&#x02010;NF186 antibody, and anti&#x02010;FLAG antibody stained cells expressing NF155, NF186, and truncation variants of NF155, respectively, and showed two apparent peaks in the histograms (Figure&#x000a0;<xref rid="acn370036-fig-0002" ref-type="fig">2</xref>).</p></sec><sec id="acn370036-sec-0016"><label>3.3</label><title>Epitope Mapping of <styled-content style="fixed-case" toggle="no">NF155</styled-content> Antibodies by Flow Cytometric <styled-content style="fixed-case" toggle="no">CBA</styled-content>
</title><p>To determine the epitopes for the anti&#x02010;NF155 antibodies in this large cohort of anti&#x02010;NF155+ patients, the flow cytometric CBA was adopted (Figure&#x000a0;<xref rid="acn370036-supitem-0001" ref-type="supplementary-material">S1</xref>). Representative results are shown in Figure&#x000a0;<xref rid="acn370036-fig-0002" ref-type="fig">2</xref>, and a data summary is presented in Table&#x000a0;<xref rid="acn370036-tbl-0003" ref-type="table">3</xref>. None of the serum samples from the IgG4 anti&#x02010;NF155+ patients reacted with NF186 (Table&#x000a0;<xref rid="acn370036-tbl-0003" ref-type="table">3</xref> and Figure&#x000a0;<xref rid="acn370036-fig-0002" ref-type="fig">2</xref>). Surprisingly, all 100 of these serum samples bound to Fn3&#x02010;Fn4. However, none of the 100 samples reacted with Fn3 or Fn4 alone, except for one sample that also bound to Fn3. These findings led us to hypothesize that the main epitopes existed in the transition region between Fn3 and Fn4. However, none of the samples from the IgG4 anti&#x02010;NF155+ patients reacted with shorter Fn3&#x02010;Fn4, in which both sides of Fn3&#x02010;Fn4 were truncated. As expected, none of the eight healthy control serum samples reacted with either the NF isoforms (NF155 and NF186) or the truncated variants of NF155 (Fn3&#x02010;Fn4, Fn3, Fn4, and shorter Fn3&#x02010;Fn4) (Table&#x000a0;<xref rid="acn370036-tbl-0003" ref-type="table">3</xref>, Figure&#x000a0;<xref rid="acn370036-fig-0002" ref-type="fig">2</xref>, and Figure&#x000a0;<xref rid="acn370036-supitem-0001" ref-type="supplementary-material">S1</xref>). When the four non&#x02010;IgG4 anti&#x02010;NF155+ patients were evaluated, all four serum samples reacted with Fn3&#x02010;Fn4, while none of the samples reacted with NF186 or the other truncation variants of NF155 (Table&#x000a0;<xref rid="acn370036-tbl-0003" ref-type="table">3</xref> and Figure&#x000a0;<xref rid="acn370036-fig-0002" ref-type="fig">2</xref>), demonstrating similar characteristics to the samples from the IgG4 anti&#x02010;NF155+ patients.</p><table-wrap position="float" id="acn370036-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Summary of the results obtained by flow cytometric CBA among the anti&#x02010;NF155+ AN patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">NF186, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">NF155, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Fn3&#x02010;Fn4, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Fn3, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Fn4, <italic toggle="yes">n</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Shorter Fn3&#x02010;Fn4, <italic toggle="yes">n</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>IgG4 anti&#x02010;NF155+ AN</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;100</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">100 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">100 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Non&#x02010;IgG4 anti&#x02010;NF155+ AN</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;4</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Healthy controls</p>
<p>
<italic toggle="yes">N</italic>&#x02009;=&#x02009;8</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot id="acn370036-ntgp-0004"><fn id="acn370036-note-0005"><p>Abbreviations: AN, autoimmune nodopathy; CBA, cell&#x02010;based assay; Fn3, third fibronectin type III domain; Fn4, fourth fibronectin type III domain; <italic toggle="yes">N</italic>, number of patients collated; <italic toggle="yes">n</italic>, number of positive patients; NF155, neurofascin 155; NF186, neurofascin 186.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acn370036-sec-0017"><label>3.4</label><title>Validation of the Epitope Mapping for the Anti&#x02010;<styled-content style="fixed-case" toggle="no">NF155</styled-content> Antibodies by Western Blotting</title><p>Representative serum samples from five IgG4 anti&#x02010;NF155+ patients, one non&#x02010;IgG4 anti&#x02010;NF155+ patient, and one healthy control were further selected for western blotting analysis. The sera from all six anti&#x02010;NF155+ patients (Pts. 1, 2, 7, 63, 100, and 104) showed specific bands in the lanes containing full&#x02010;length NF155 and Fn3&#x02010;Fn4, although the serum sample from the non&#x02010;IgG4 anti&#x02010;NF155+ patient (Pt. 104) had a very weak reaction with full&#x02010;length NF155 (Figure&#x000a0;<xref rid="acn370036-fig-0003" ref-type="fig">3</xref>). The sample that was reactive toward Fn3 in the flow cytometric CBA did not show any reactivity to Fn3 in the western blotting analysis. The healthy control sample did not react with any of the proteins (Figure&#x000a0;<xref rid="acn370036-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="acn370036-fig-0003"><label>FIGURE 3</label><caption><p>Immunoblotting analysis to validate the reactivities of anti&#x02010;NF155+ patient sera against specific NF isoforms and truncated variants of NF155. Serum samples from five IgG4 anti&#x02010;NF155+ patients (Pts. 1, 2, 7, 63, 100; blue), one non&#x02010;IgG4 anti&#x02010;NF155+ patient (Pt. 104; green), and one healthy control were selected as sources for the primary antibodies. All serum samples from the IgG4 anti&#x02010;NF155+ patients were reactive toward NF155&#x02010;tGFP (lane 2) and Fn3&#x02010;Fn4&#x02010;FLAG&#x02010;GPI (lane 4). The serum sample from the one non&#x02010;IgG4 anti&#x02010;NF155+ patient reacted with Fn3&#x02010;Fn4 only (lane 4). The serum sample from the healthy control showed no reactivity toward the NF isoforms or the truncated variants of NF155. Fn3, third fibronectin type III domain; Fn4, fourth fibronectin type III domain; GPI, glycosylphosphatidylinositol; HC, healthy control; HEK293, human embryonic kidney 293 cells; M, molecular weight markers; NF, neurofascin; NF155, neurofascin 155; NF186, neurofascin 186; Pt., Patient; tGFP, turbo GFP.</p></caption><graphic xlink:href="ACN3-12-1034-g001" position="anchor" id="jats-graphic-5"/></fig></sec></sec><sec sec-type="discussion" id="acn370036-sec-0018"><label>4</label><title>Discussion</title><p>This epitope mapping study for anti&#x02010;NF155 antibodies utilizing sera from 104 anti&#x02010;NF155+ patients produced the following findings: (1) none of the anti&#x02010;NF155+ patient sera were reactive toward NF186; (2) all of the anti&#x02010;NF155+ patient sera bound to Fn3&#x02010;Fn4; (3) none of the anti&#x02010;NF155+ patient sera were reactive toward Fn4 or shorter Fn3&#x02010;Fn4; (4) the serum of only one IgG4 anti&#x02010;NF155+ patient bound to Fn3; (5) sera from four non&#x02010;IgG4 anti&#x02010;NF155+ AN patients also reacted with Fn3&#x02010;Fn4.</p><p>NF155 and NF186 have very similar structures, with the only differences being that NF155 lacks the mucin domain and Fn5, while NF186 lacks Fn3 [<xref rid="acn370036-bib-0028" ref-type="bibr">28</xref>]. The Fn3 domain is known to interact with integrins and has been implicated in the initial axoglial interaction through its arginine, glycine, and aspartic acid (RGD) motif [<xref rid="acn370036-bib-0029" ref-type="bibr">29</xref>]. This RGD sequence within NF155 was also reported to facilitate neurite development and neuronal cell spreading [<xref rid="acn370036-bib-0012" ref-type="bibr">12</xref>]. Given our findings that IgG4 anti&#x02010;NF155+ patient sera were not reactive toward NF186, we hypothesized that the antigenic epitopes for anti&#x02010;NF155 antibodies are located around the extracellular Fn3 domain unique to NF155, consistent with previous reports [<xref rid="acn370036-bib-0008" ref-type="bibr">8</xref>, <xref rid="acn370036-bib-0026" ref-type="bibr">26</xref>, <xref rid="acn370036-bib-0030" ref-type="bibr">30</xref>].</p><p>With confirmed expression of NF155, NF186, and several truncated variants of NF155 on the surface of HEK293 cells by western blotting and flow cytometric CBA analyses, the flow cytometric CBA using live human cell lines, which provides more accurate results than a fixed CBA [<xref rid="acn370036-bib-0031" ref-type="bibr">31</xref>, <xref rid="acn370036-bib-0032" ref-type="bibr">32</xref>], clarified that all examined sera from IgG4 anti&#x02010;NF155+ patients were reactive toward Fn3&#x02010;Fn4, indicating that this region contains the pivotal epitope for IgG4 anti&#x02010;NF155 antibodies. We further investigated the binding capacity of IgG4 anti&#x02010;NF155 antibodies against Fn3 or Fn4 alone to identify more specific epitopes. However, none of the sera, except for one sample from an IgG4 anti&#x02010;NF155+ patient, reacted with Fn3. Although we tested the reactivity of the IgG4 anti&#x02010;NF155+ patient sera against shorter Fn3&#x02010;Fn4, which contained the transition part between Fn3 and Fn4, none of the samples reacted with this truncated variant. Finally, we confirmed compatible results between the western blotting and flow cytometric CBA analyses using representative samples. Taken together, IgG4 anti&#x02010;NF155 antibodies are likely to recognize conformational epitopes in Fn3&#x02010;Fn4, but not in Fn3 or Fn4 alone.</p><p>To our knowledge, only a few reports have mentioned epitopes for anti&#x02010;NF155 antibodies [<xref rid="acn370036-bib-0012" ref-type="bibr">12</xref>, <xref rid="acn370036-bib-0018" ref-type="bibr">18</xref>, <xref rid="acn370036-bib-0029" ref-type="bibr">29</xref>]. One epitope mapping study found that the Fn1&#x02010;Fn4 region of NF155 contained the main target epitope for IgG4 NF155 antibodies in 30 of 38 patients (79%) because their sera did not bind to NF155 that lacked this region [<xref rid="acn370036-bib-0013" ref-type="bibr">13</xref>]. However, the study also found that the autoantibodies from 16 of 38 patients (42%) did not bind to Fn1&#x02010;Fn4 [<xref rid="acn370036-bib-0013" ref-type="bibr">13</xref>]. Ng et&#x000a0;al. [<xref rid="acn370036-bib-0026" ref-type="bibr">26</xref>] mapped the domains recognized by the autoantibodies of two IgG4 anti&#x02010;NF155+ CIDP patients using truncation variants of NF155 and NF186, and found that the autoantibodies from both patients bound to Fn3&#x02010;Fn4, but not Fn3 or Fn4 alone. Similarly, Stengel and colleagues reported that the sera from two other IgG4 anti&#x02010;NF155+ patients were immunoreactive toward Fn3&#x02010;Fn4 [<xref rid="acn370036-bib-0008" ref-type="bibr">8</xref>]. The findings of these studies were generally in accordance with the present results despite their limited numbers of cases. Our study with a much larger number of patients proved that the specific epitopes for IgG4 anti&#x02010;NF155 antibodies are generally located in Fn3&#x02010;Fn4.</p><p>Two specific <italic toggle="yes">HLA</italic> class II alleles, <italic toggle="yes">HLA&#x02010;DRB1*15:01</italic> and <italic toggle="yes">HLA&#x02010;DRB1*15:02</italic>, were found to be present in &#x0003e;&#x02009;90% of IgG4 anti&#x02010;NF155+ patients [<xref rid="acn370036-bib-0015" ref-type="bibr">15</xref>, <xref rid="acn370036-bib-0033" ref-type="bibr">33</xref>], representing a significantly higher proportion compared with the general population. Class II HLA molecules on antigen&#x02010;presenting cells play a role in showing antigen peptides to CD4+ T cells with specific T&#x02010;cell receptors [<xref rid="acn370036-bib-0034" ref-type="bibr">34</xref>]. Because HLA&#x02010;DRB1*15:01 and HLA&#x02010;DRB1*15:02 have only one difference at the 86th amino acid, located in pocket 1 of the peptide&#x02010;binding groove [<xref rid="acn370036-bib-0035" ref-type="bibr">35</xref>, <xref rid="acn370036-bib-0036" ref-type="bibr">36</xref>], both of these HLA class II molecules could present common NF155 peptides to CD4+ T cells [<xref rid="acn370036-bib-0001" ref-type="bibr">1</xref>, <xref rid="acn370036-bib-0033" ref-type="bibr">33</xref>]. Because B cells, in addition to their function in antibody production, also express high levels of MHC class II molecules and can present antigens [<xref rid="acn370036-bib-0037" ref-type="bibr">37</xref>], B cells with both HLA&#x02010;DRB1*15 and B cell receptors against epitopes in Fn3&#x02010;Fn4 may provide common peptides to specific CD4+ T cells.</p><p>This study also evaluated four non&#x02010;IgG4 anti&#x02010;NF155+ patients. Although it remains uncertain whether IgG4 anti&#x02010;NF155+ and non&#x02010;IgG4 anti&#x02010;NF155+ AN are identical in terms of the roles of autoantibodies and their pathomechanisms, the findings for these patients were similar to those for IgG4 anti&#x02010;NF155+ patients. Further studies are needed to clarify this point.</p><p>The present study had some limitations. First, the Fn3&#x02010;Fn4 region that we identified as containing the specific epitope for anti&#x02010;NF155 antibodies still contains approximately 200 amino acids. Although our results suggest that the anti&#x02010;NF155 antibodies recognize a conformational structure within Fn3&#x02010;Fn4, western blotting revealed that all patient samples were reactive toward processed full&#x02010;length NF155 and Fn3&#x02010;Fn4 after SDS&#x02010;polyacrylamide gel electrophoresis. Because some &#x003b2;&#x02010;sheet proteins, including Fn domains, were reported to show resistance against SDS denaturation [<xref rid="acn370036-bib-0038" ref-type="bibr">38</xref>], the conformational epitopes in Fn3&#x02010;Fn4 may be maintained under the experimental conditions used in this study. Further approaches to narrow down the target epitopes will be needed in future studies. Second, we did not evaluate the effects of the sugar chains in glycosylated NF155 and its different domain constructs on the autoantibody binding. The sugar chains in NF155 are located in Fn4 on two amino acids (Asn973 and Asn988), with no chains found in Fn3 [<xref rid="acn370036-bib-0039" ref-type="bibr">39</xref>]. N&#x02010;glycosylations are essential for the construction of the paranodal complex [<xref rid="acn370036-bib-0040" ref-type="bibr">40</xref>]. Notably, the binding of NF155 to CNTN1 requires N&#x02010;glycosylation, and in turn, NF155 binds to glycosylated CNTN1 using mannose&#x02010;rich oligosaccharides [<xref rid="acn370036-bib-0041" ref-type="bibr">41</xref>]. Chataigner et&#x000a0;al. [<xref rid="acn370036-bib-0042" ref-type="bibr">42</xref>] reported that either CNTN1 or NF155, but not both, is rich in mannose glycans and promotes heterophilic cell&#x02013;cell interactions. In a previous study that investigated the contribution of NF155 glycosylation [<xref rid="acn370036-bib-0013" ref-type="bibr">13</xref>], deglycosylation by either N&#x02010;glycosidase F or tunicamycin extinguished the autoantibody binding to NF155. Labasque et&#x000a0;al. [<xref rid="acn370036-bib-0043" ref-type="bibr">43</xref>] determined that the immunoreactivity was directed against the Ig domains of CNTN1 and was N&#x02010;glycan&#x02010;dependent. These types of analyses will be considered for our future studies.</p><p>In conclusion, this epitope mapping study involving a large cohort of Japanese anti&#x02010;NF155+ AN patients has provided detailed information about the specificity of anti&#x02010;NF155 antibodies. We propose that Fn3&#x02010;Fn4, but not Fn3 or Fn4 alone, constitutes the primary epitope for anti&#x02010;NF155 antibodies. This determination allows us to understand the pathogenesis of the disorder more deeply and to develop innovative epitope&#x02010;specific therapeutic strategies, such as decoy antigen therapies and more specific diagnostic procedures. Further efforts are warranted to determine more specific epitopes for these autoantibodies.</p></sec><sec id="acn370036-sec-0019"><title>Author Contributions</title><p>A.A., H.O., X.Z., T.T., R.Y., J.K., and N.I. designed and conceptualized the study, collected the data, analyzed the data, and drafted the manuscript.</p></sec><sec id="acn370036-sec-0021"><title>Ethics Statement</title><p>The research protocols for the study were approved by the Kyushu University Ethics Committee.</p></sec><sec sec-type="conclusions" id="acn370036-sec-0023"><title>Consent</title><p>An opt&#x02010;out recruitment method was adopted for the present study.</p></sec><sec sec-type="COI-statement" id="acn370036-sec-0022"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="acn370036-supitem-0001" position="float" content-type="local-data"><caption><p>
Figure S1.
</p></caption><media xlink:href="ACN3-12-1034-s001.pdf"/></supplementary-material></sec></body><back><ack id="acn370036-sec-0020"><title>Acknowledgments</title><p>A.A. acknowledges financial support from a scholarship provided by the Egyptian Ministry of Higher Education. The authors thank Cosmic Corporation for its cooperation and support in the study. The authors also thank Alison Sherwin, PhD, from Edanz (<ext-link xlink:href="https://jp.edanz.com/ac" ext-link-type="uri">https://jp.edanz.com/ac</ext-link>) for editing a draft of this manuscript.</p></ack><sec sec-type="data-availability" id="acn370036-sec-0025"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="acn370036-bibl-0001"><title>References</title><ref id="acn370036-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acn370036-cit-0001">
<string-name>
<given-names>J.</given-names>
<surname>Kira</surname>
</string-name>, &#x0201c;<article-title>Anti&#x02010;Neurofascin 155 Antibody&#x02010;Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism</article-title>,&#x0201d; <source>Frontiers in Neurology</source>
<volume>12</volume>, no. <issue>639</issue> (<year>2021</year>): <elocation-id>665136</elocation-id>, <pub-id pub-id-type="doi">10.3389/fneur.2021.665136</pub-id>.<pub-id pub-id-type="pmid">34177770</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acn370036-cit-0002">
<string-name>
<given-names>J.</given-names>
<surname>Wolbert</surname>
</string-name>, <string-name>
<given-names>M. I.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Meyer zu Horste</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Su</surname>
</string-name>, &#x0201c;<article-title>Deciphering Immune Mechanisms in Chronic Inflammatory Demyelinating Polyneuropathies</article-title>,&#x0201d; <source>JCI Insight</source>
<volume>5</volume>, no. <issue>3</issue> (<year>2020</year>): <elocation-id>132411</elocation-id>.<pub-id pub-id-type="pmid">32051341</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acn370036-cit-0003">
<string-name>
<given-names>B. C.</given-names>
<surname>Kieseier</surname>
</string-name>, <string-name>
<given-names>E. K.</given-names>
<surname>Mathey</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Sommer</surname>
</string-name>, and <string-name>
<given-names>H.&#x02010;P.</given-names>
<surname>Hartung</surname>
</string-name>, &#x0201c;<article-title>Immune&#x02010;Mediated Neuropathies</article-title>,&#x0201d; <source>Nature Reviews Disease Primers</source>
<volume>4</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>1</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="acn370036-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acn370036-cit-0004">
<string-name>
<given-names>H.</given-names>
<surname>Ogata</surname>
</string-name> and <string-name>
<given-names>R.</given-names>
<surname>Yamasaki</surname>
</string-name>, &#x0201c;<article-title>Anti&#x02010;Neurofascin 155 Antibody&#x02010;Related Neuropathy</article-title>,&#x0201d; <source>Clinical and Experimental Neuroimmunology</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>54</fpage>&#x02013;<lpage>64</lpage>.</mixed-citation></ref><ref id="acn370036-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acn370036-cit-0005">
<string-name>
<given-names>M. C.</given-names>
<surname>Dalakas</surname>
</string-name>, &#x0201c;<article-title>Advances in the Diagnosis, Pathogenesis and Treatment of CIDP</article-title>,&#x0201d; <source>Nature Reviews. Neurology</source>
<volume>7</volume>, no. <issue>9</issue> (<year>2011</year>): <fpage>507</fpage>&#x02013;<lpage>517</lpage>.<pub-id pub-id-type="pmid">21844897</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acn370036-cit-0006">
<string-name>
<given-names>C.</given-names>
<surname>Bunschoten</surname>
</string-name>, <string-name>
<given-names>B. C.</given-names>
<surname>Jacobs</surname>
</string-name>, <string-name>
<given-names>P. Y. K.</given-names>
<surname>Van den Bergh</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Progress in Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy</article-title>,&#x0201d; <source>Lancet Neurology</source>
<volume>18</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>784</fpage>&#x02013;<lpage>794</lpage>.<pub-id pub-id-type="pmid">31076244</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acn370036-cit-0007">
<string-name>
<given-names>P. Y. K.</given-names>
<surname>Van den Bergh</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>van Doorn</surname>
</string-name>, <string-name>
<given-names>R. D. M.</given-names>
<surname>Hadden</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>European Academy of Neurology/Peripheral Nerve Society Guideline on Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Report of a Joint Task Force&#x02014;Second Revision</article-title>,&#x0201d; <source>European Journal of Neurology</source>
<volume>28</volume>, no. <issue>11</issue> (<year>2021</year>): <fpage>3556</fpage>&#x02013;<lpage>3583</lpage>.<pub-id pub-id-type="pmid">34327760</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acn370036-cit-0008">
<string-name>
<given-names>H.</given-names>
<surname>Stengel</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Vural</surname>
</string-name>, <string-name>
<given-names>A.&#x02010;M.</given-names>
<surname>Brunder</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Anti&#x02013;Pan&#x02010;Neurofascin IgG3 as a Marker of Fulminant Autoimmune Neuropathy</article-title>,&#x0201d; <source>Neurology: Neuroimmunology &#x00026; Neuroinflammation</source>
<volume>6</volume>, no. <issue>5</issue> (<year>2019</year>): <elocation-id>e603</elocation-id>, <pub-id pub-id-type="doi">10.1212/NXI.0000000000000603</pub-id>.<pub-id pub-id-type="pmid">31454780</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acn370036-cit-0009">
<string-name>
<given-names>M.</given-names>
<surname>Kriebel</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wuchter</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Trinks</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Volkmer</surname>
</string-name>, &#x0201c;<article-title>Neurofascin: A Switch Between Neuronal Plasticity and Stability</article-title>,&#x0201d; <source>International Journal of Biochemistry &#x00026; Cell Biology</source>
<volume>44</volume>, no. <issue>5</issue> (<year>2012</year>): <fpage>694</fpage>&#x02013;<lpage>697</lpage>.<pub-id pub-id-type="pmid">22306302</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acn370036-cit-0010">
<string-name>
<given-names>D. L.</given-names>
<surname>Sherman</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Tait</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Melrose</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neurofascins Are Required to Establish Axonal Domains for Saltatory Conduction</article-title>,&#x0201d; <source>Neuron</source>
<volume>48</volume>, no. <issue>5</issue> (<year>2005</year>): <fpage>737</fpage>&#x02013;<lpage>742</lpage>.<pub-id pub-id-type="pmid">16337912</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acn370036-cit-0011">
<string-name>
<given-names>J.&#x02010;I.</given-names>
<surname>Kira</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Yamasaki</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Ogata</surname>
</string-name>, &#x0201c;<article-title>Anti&#x02010;Neurofascin Autoantibody and Demyelination</article-title>,&#x0201d; <source>Neurochemistry International</source>
<volume>130</volume> (<year>2019</year>): <elocation-id>104360</elocation-id>.<pub-id pub-id-type="pmid">30582947</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acn370036-cit-0012">
<string-name>
<given-names>D.</given-names>
<surname>Koticha</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Babiarz</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Kane&#x02010;Goldsmith</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Jacob</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Raju</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Grumet</surname>
</string-name>, &#x0201c;<article-title>Cell Adhesion and Neurite Outgrowth Are Promoted by Neurofascin NF155 and Inhibited by NF186</article-title>,&#x0201d; <source>Molecular and Cellular Neurosciences</source>
<volume>30</volume>, no. <issue>1</issue> (<year>2005</year>): <fpage>137</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">16061393</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="acn370036-cit-0013">
<string-name>
<given-names>J. J.</given-names>
<surname>Devaux</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Miura</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Fukami</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neurofascin&#x02010;155 IgG4 in Chronic Inflammatory Demyelinating Polyneuropathy</article-title>,&#x0201d; <source>Neurology</source>
<volume>86</volume>, no. <issue>9</issue> (<year>2016</year>): <fpage>800</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26843559</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="acn370036-cit-0014">
<string-name>
<given-names>L.</given-names>
<surname>Kouton</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Boucraut</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Devaux</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Electrophysiological Features of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated With IgG4 Antibodies Targeting Neurofascin 155 or Contactin 1 Glycoproteins</article-title>,&#x0201d; <source>Clinical Neurophysiology</source>
<volume>131</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>921</fpage>&#x02013;<lpage>927</lpage>.<pub-id pub-id-type="pmid">32078921</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="acn370036-cit-0015">
<string-name>
<given-names>L.</given-names>
<surname>Martinez&#x02010;Martinez</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Lleix&#x000e0;</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Boera&#x02010;Carnicero</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Anti&#x02010;NF155 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Strongly Associates to HLA&#x02010;DRB15</article-title>,&#x0201d; <source>Journal of Neuroinflammation</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>224</fpage>.<pub-id pub-id-type="pmid">29145880</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="acn370036-cit-0016">
<string-name>
<given-names>L.</given-names>
<surname>Querol</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Nogales&#x02010;Gadea</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Rojas&#x02010;Garcia</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neurofascin IgG4 Antibodies in CIDP Associate With Disabling Tremor and Poor Response to IVIg</article-title>,&#x0201d; <source>Neurology</source>
<volume>82</volume>, no. <issue>10</issue> (<year>2014</year>): <fpage>879</fpage>&#x02013;<lpage>886</lpage>.<pub-id pub-id-type="pmid">24523485</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="acn370036-cit-0017">
<string-name>
<given-names>M. C.</given-names>
<surname>Dalakas</surname>
</string-name>, &#x0201c;<article-title>IgG4&#x02010;Mediated Neurologic Autoimmunities</article-title>,&#x0201d; <source>Neurology: Neuroimmunology &#x00026; Neuroinflammation</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2021</year>): <elocation-id>e1116</elocation-id>.</mixed-citation></ref><ref id="acn370036-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="acn370036-cit-0018">
<string-name>
<given-names>C.</given-names>
<surname>Manso</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Querol</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Lleix&#x000e0;</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Anti&#x02013;Neurofascin&#x02010;155 IgG4 Antibodies Prevent Paranodal Complex Formation In&#x000a0;Vivo</article-title>,&#x0201d; <source>Journal of Clinical Investigation</source>
<volume>129</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>2222</fpage>&#x02013;<lpage>2236</lpage>.<pub-id pub-id-type="pmid">30869655</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="acn370036-cit-0019">
<string-name>
<given-names>L.</given-names>
<surname>Mart&#x000ed;n&#x02010;Aguilar</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Lleix&#x000e0;</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Pascual&#x02010;Go&#x000f1;i</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Clinical and Laboratory Features in Anti&#x02010;NF155 Autoimmune Nodopathy</article-title>,&#x0201d; <source>Neurology: Neuroimmunology &#x00026; Neuroinflammation</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2021</year>): <elocation-id>e1098</elocation-id>.<pub-id pub-id-type="pmid">34728497</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="acn370036-cit-0020">
<string-name>
<given-names>H.</given-names>
<surname>Koike</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kadoya</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kaida</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Paranodal Dissection in Chronic Inflammatory Demyelinating Polyneuropathy With Anti&#x02010;Neurofascin&#x02010;155 and Anti&#x02010;Contactin&#x02010;1 Antibodies</article-title>,&#x0201d; <source>Journal of Neurology, Neurosurgery, and Psychiatry</source>
<volume>88</volume>, no. <issue>6</issue> (<year>2017</year>): <fpage>465</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">28073817</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="acn370036-cit-0021">
<string-name>
<given-names>I.</given-names>
<surname>Koneczny</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Tzartos</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Man&#x000e9;&#x02010;Damas</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>IgG4 Autoantibodies in Organ&#x02010;Specific Autoimmunopathies: Reviewing Class Switching, Antibody&#x02010;Producing Cells, and Specific Immunotherapies</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>13</volume> (<year>2022</year>): <elocation-id>834342</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2022.834342</pub-id>.<pub-id pub-id-type="pmid">35401530</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="acn370036-cit-0022">
<string-name>
<given-names>M.</given-names>
<surname>Marino</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Basile</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Spagni</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Long&#x02010;Lasting Rituximab&#x02010;Induced Reduction of Specific&#x02014;But Not Total&#x02014;IgG4 in MuSK&#x02010;Positive Myasthenia Gravis</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>11</volume> (<year>2020</year>): <elocation-id>613</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2020.00613</pub-id>.<pub-id pub-id-type="pmid">32431692</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="acn370036-cit-0023">
<string-name>
<given-names>L.</given-names>
<surname>Jiao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Xiang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ruan</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Guo</surname>
</string-name>, &#x0201c;<article-title>Efficacy of Low Dose Rituximab in Treatment&#x02010;Resistant CIDP With Antibodies Against NF&#x02010;155</article-title>,&#x0201d; <source>Journal of Neuroimmunology</source>
<volume>345</volume> (<year>2020</year>): <elocation-id>577280</elocation-id>.<pub-id pub-id-type="pmid">32563125</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="acn370036-cit-0024">
<string-name>
<given-names>I.</given-names>
<surname>Shimanovich</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Baumann</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Schmidt</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Zillikens</surname>
</string-name>, and <string-name>
<given-names>C. M.</given-names>
<surname>Hammers</surname>
</string-name>, &#x0201c;<article-title>Long&#x02010;Term Outcomes of Rituximab Therapy in Pemphigus</article-title>,&#x0201d; <source>Journal of the European Academy of Dermatology and Venereology</source>
<volume>34</volume>, no. <issue>12</issue> (<year>2020</year>): <fpage>2884</fpage>&#x02013;<lpage>2889</lpage>.<pub-id pub-id-type="pmid">32367562</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="acn370036-cit-0025">
<string-name>
<given-names>N.</given-names>
<surname>Sinmaz</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Nguyen</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Tea</surname>
</string-name>, <string-name>
<given-names>R. C.</given-names>
<surname>Dale</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Brilot</surname>
</string-name>, &#x0201c;<article-title>Mapping Autoantigen Epitopes: Molecular Insights Into Autoantibody&#x02010;Associated Disorders of the Nervous System</article-title>,&#x0201d; <source>Journal of Neuroinflammation</source>
<volume>13</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>219</fpage>.<pub-id pub-id-type="pmid">27577085</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="acn370036-cit-0026">
<string-name>
<given-names>J. K. M.</given-names>
<surname>Ng</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Malotka</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Kawakami</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neurofascin as a Target for Autoantibodies in Peripheral Neuropathies</article-title>,&#x0201d; <source>Neurology</source>
<volume>79</volume>, no. <issue>23</issue> (<year>2012</year>): <fpage>2241</fpage>&#x02013;<lpage>2248</lpage>.<pub-id pub-id-type="pmid">23100406</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="acn370036-cit-0027">
<string-name>
<given-names>H.</given-names>
<surname>Ogata</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Yamasaki</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Hiwatashi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Characterization of IgG4 Anti&#x02010;Neurofascin 155 Antibody&#x02010;Positive Polyneuropathy</article-title>,&#x0201d; <source>Annals of Clinical Translational Neurology</source>
<volume>2</volume>, no. <issue>10</issue> (<year>2015</year>): <fpage>960</fpage>&#x02013;<lpage>971</lpage>.<pub-id pub-id-type="pmid">26478896</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="acn370036-cit-0028">
<string-name>
<given-names>H.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Focia</surname>
</string-name>, and <string-name>
<given-names>X.</given-names>
<surname>He</surname>
</string-name>, &#x0201c;<article-title>Homophilic Adhesion Mechanism of Neurofascin, a Member of the L1 Family of Neural Cell Adhesion Molecules</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>286</volume>, no. <issue>1</issue> (<year>2011</year>): <fpage>797</fpage>&#x02013;<lpage>805</lpage>.<pub-id pub-id-type="pmid">21047790</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="acn370036-cit-0029">
<string-name>
<given-names>M. L.</given-names>
<surname>Feltri</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Graus Porta</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Previtali</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Conditional Disruption of Beta 1 Integrin in Schwann Cells Impedes Interactions With Axons</article-title>,&#x0201d; <source>Journal of Cell Biology</source>
<volume>156</volume>, no. <issue>1</issue> (<year>2002</year>): <fpage>199</fpage>&#x02013;<lpage>209</lpage>, <pub-id pub-id-type="doi">10.1083/jcb.200109021</pub-id>.<pub-id pub-id-type="pmid">11777940</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="acn370036-cit-0030">
<string-name>
<given-names>E.</given-names>
<surname>Burnor</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhou</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Neurofascin Antibodies in Autoimmune, Genetic, and Idiopathic Neuropathies</article-title>,&#x0201d; <source>Neurology</source>
<volume>90</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>e31</fpage>&#x02013;<lpage>e38</lpage>.<pub-id pub-id-type="pmid">29187518</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="acn370036-cit-0031">
<string-name>
<given-names>G.</given-names>
<surname>Spagni</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gastaldi</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Businaro</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Comparison of Fixed and Live Cell&#x02010;Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis</article-title>,&#x0201d; <source>Neurology: Neuroimmunology &#x00026; Neuroinflammation</source>
<volume>10</volume>, no. <issue>1</issue> (<year>2023</year>): <elocation-id>e200038</elocation-id>.</mixed-citation></ref><ref id="acn370036-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="acn370036-cit-0032">
<string-name>
<given-names>P. J.</given-names>
<surname>Waters</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Komorowski</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Woodhall</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Multicenter Comparison of MOG&#x02010;IgG Cell&#x02010;Based Assays</article-title>,&#x0201d; <source>Neurology</source>
<volume>92</volume>, no. <issue>11</issue> (<year>2019</year>): <fpage>e1250</fpage>&#x02013;<lpage>e1255</lpage>.<pub-id pub-id-type="pmid">30728305</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="acn370036-cit-0033">
<string-name>
<given-names>H.</given-names>
<surname>Ogata</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Isobe</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Unique HLA Haplotype Associations in IgG4 Anti&#x02010;Neurofascin 155 Antibody&#x02010;Positive Chronic Inflammatory Demyelinating Polyneuropathy</article-title>,&#x0201d; <source>Journal of Neuroimmunology</source>
<volume>339</volume> (<year>2020</year>): <elocation-id>577139</elocation-id>.<pub-id pub-id-type="pmid">31864140</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="acn370036-cit-0034">
<string-name>
<given-names>A.</given-names>
<surname>Couture</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Garnier</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Docagne</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>HLA&#x02010;Class II Artificial Antigen Presenting Cells in CD4+ T Cell&#x02010;Based Immunotherapy</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>10</volume> (<year>2019</year>): <elocation-id>1081</elocation-id>.<pub-id pub-id-type="pmid">31156634</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="acn370036-cit-0035">
<string-name>
<given-names>K. J.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Pyrdol</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gauthier</surname>
</string-name>, <string-name>
<given-names>D. C.</given-names>
<surname>Wiley</surname>
</string-name>, and <string-name>
<given-names>K. W.</given-names>
<surname>Wucherpfennig</surname>
</string-name>, &#x0201c;<article-title>Crystal Structure of HLA&#x02010;DR2 (DRA*0101, DRB1*1501) Complexed With a Peptide From Human Myelin Basic Protein</article-title>,&#x0201d; <source>Journal of Experimental Medicine</source>
<volume>188</volume>, no. <issue>8</issue> (<year>1998</year>): <fpage>1511</fpage>&#x02013;<lpage>1520</lpage>.<pub-id pub-id-type="pmid">9782128</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="acn370036-cit-0036">
<string-name>
<given-names>S. G. E.</given-names>
<surname>Marsh</surname>
</string-name> and <string-name>
<given-names>J. G.</given-names>
<surname>Bodmer</surname>
</string-name>, &#x0201c;<article-title>HLA Class II Region Nucleotide Sequences, 1995</article-title>,&#x0201d; <source>Tissue Antigens</source>
<volume>46</volume>, no. <issue>3</issue> (<year>1995</year>): <fpage>258</fpage>&#x02013;<lpage>280</lpage>.<pub-id pub-id-type="pmid">8525485</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="acn370036-cit-0037">
<string-name>
<given-names>L. N.</given-names>
<surname>Adler</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Bhamidipati</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Other Function: Class II&#x02010;Restricted Antigen Presentation by B Cells</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>8</volume> (<year>2017</year>): <elocation-id>319</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2017.00319</pub-id>.<pub-id pub-id-type="pmid">28386257</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="acn370036-cit-0038">
<string-name>
<given-names>M. M.</given-names>
<surname>Nielsen</surname>
</string-name>, <string-name>
<given-names>K. K.</given-names>
<surname>Andersen</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Westh</surname>
</string-name>, and <string-name>
<given-names>D. E.</given-names>
<surname>Otzen</surname>
</string-name>, &#x0201c;<article-title>Unfolding of &#x003b2;&#x02010;Sheet Proteins in SDS</article-title>,&#x0201d; <source>Biophysical Journal</source>
<volume>92</volume>, no. <issue>10</issue> (<year>2007</year>): <fpage>3674</fpage>&#x02013;<lpage>3685</lpage>.<pub-id pub-id-type="pmid">17351005</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0039"><label>39</label><mixed-citation publication-type="miscellaneous" id="acn370036-cit-0039">
<article-title>&#x0201c;NFASC&#x02014;Neurofascin&#x02014;Homo Sapiens (Human)|UniProtKB|UniProt&#x0201d;</article-title>, accessed April 26, 2023, <ext-link xlink:href="https://www.uniprot.org/uniprotkb/O94856/entry" ext-link-type="uri">https://www.uniprot.org/uniprotkb/O94856/entry</ext-link>.</mixed-citation></ref><ref id="acn370036-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="acn370036-cit-0040">
<string-name>
<given-names>K. W.</given-names>
<surname>Moremen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Tiemeyer</surname>
</string-name>, and <string-name>
<given-names>A. V.</given-names>
<surname>Nairn</surname>
</string-name>, &#x0201c;<article-title>Vertebrate Protein Glycosylation: Diversity, Synthesis and Function</article-title>,&#x0201d; <source>Nature Reviews. Molecular Cell Biology</source>
<volume>13</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>448</fpage>&#x02013;<lpage>462</lpage>.<pub-id pub-id-type="pmid">22722607</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="acn370036-cit-0041">
<string-name>
<given-names>C.</given-names>
<surname>Bonnon</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bel</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Goutebroze</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Maigret</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Girault</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Faivre&#x02010;Sarrailh</surname>
</string-name>, &#x0201c;<article-title>PGY Repeats and N&#x02010;Glycans Govern the Trafficking of Paranodin and Its Selective Association With Contactin and Neurofascin&#x02010;155</article-title>,&#x0201d; <source>Molecular Biology of the Cell</source>
<volume>18</volume>, no. <issue>1</issue> (<year>2007</year>): <fpage>229</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">17093057</pub-id>
</mixed-citation></ref><ref id="acn370036-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="acn370036-cit-0042">
<string-name>
<given-names>L. M. P.</given-names>
<surname>Chataigner</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Gogou</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>den Boer</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Structural Insights Into the Contactin 1&#x02014;Neurofascin 155 Adhesion Complex</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>13</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>6607</fpage>.</mixed-citation></ref><ref id="acn370036-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="acn370036-cit-0043">
<string-name>
<given-names>M.</given-names>
<surname>Labasque</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hivert</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Nogales&#x02010;Gadea</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Querol</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Illa</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Faivre&#x02010;Sarrailh</surname>
</string-name>, &#x0201c;<article-title>Specific Contactin N&#x02010;Glycans Are Implicated in Neurofascin Binding and Autoimmune Targeting in Peripheral Neuropathies</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>289</volume>, no. <issue>11</issue> (<year>2014</year>): <fpage>7907</fpage>&#x02013;<lpage>7918</lpage>.<pub-id pub-id-type="pmid">24497634</pub-id>
</mixed-citation></ref></ref-list></back></article>